Vol. 281, Issue 6, H2539-H2548, December 2001
Compensatory changes in Ca2+ and
myocardial O2 consumption in
-tropomyosin
transgenic hearts
Guy A.
MacGowan4,
Congwu
Du1,3,
David F.
Wieczorek6, and
Alan P.
Koretsky1,2,5
1 Pittsburgh Nuclear Magnetic Resonance Center for
Biomedical Research, 2 Department of Biological Sciences, and
3 Center for Light Microscope Imaging and Biotechnology,
Carnegie Mellon University, Pittsburgh, 15213; 4 Cardiovascular
Institute of the University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania 15213; 5 Laboratory of Functional and Molecular
Imaging, National Institute of Neurological Disease and Stroke,
Bethesda, Maryland 20892; and 6 Department of Molecular
Genetics, Biochemistry and Microbiology, University of
Cincinnati College of Medicine, Cincinnati, Ohio 45267
 |
ABSTRACT |
Transgenic
mice overexpressing
-tropomyosin have increased myofilament
Ca2+ sensitivity that we hypothesized would result in
altered relationships among pressure and heart rates, intracellular
Ca2+, and myocardial O2 consumption. In
perfused hearts from transgenic mice there was a marked negative
force-frequency response between 6 and 10 Hz with a 30 ± 3%
reduction in peak-positive first derivative of pressure development
over time (dP/dt) compared with 14 ± 2% in wild-type
mice (P < 0.001). At 8 Hz systolic pressures were normal, though peak systolic intracellular Ca2+ was
significantly reduced in transgenic mice versus wild type (726 ± 61 vs. 936 ± 67 nM, P < 0.05) indicating an
alteration in the pressure-Ca2+ relationship. Over a wide
range of positive and negative inotropic interventions there were
normal developed pressures, though marked elevations in myocardial
O2 consumption (15-54%). Because pressures are normal
and intracellular Ca2+ decreased and myocardial
O2 consumption increased, this suggests that these
abnormalities are at least in part compensatory mechanisms to the
altered myofilament function.
pressure
 |
INTRODUCTION |
TROPOMYOSIN HAS A CENTRAL
ROLE in normal myofilament function (28).
Ca2+ binding to troponin C results in displacement of
tropomyosin, which exposes actin sites to myosin binding, resulting in
myofilament shortening. Tropomyosin has three isoforms. There are more

-homodimers (27) in fast-contracting cardiac muscle
and more 
-homodimers in slow-contracting muscle. Tropomyosin 3 is
expressed in slow-twitch skeletal muscle, and is not expressed in the
murine heart at any stage of development (26). To study
the physiological significance of the
- and
-tropomyosin
isoforms, Muthuchamy and colleagues (23) developed a
transgenic (TG) mouse overexpressing
-tropomoysin in the heart.
There were no structural abnormalities, though physiological analysis
in the working heart preparation revealed abnormal diastolic function
with a reduced maximum rate of relaxation. Subsequent studies
(24) in isolated fiber bundles revealed an increase in the
activation of the thin filament by strongly bound cross bridges, an
increase in the Ca2+ sensitivity of steady-state force, and
a decrease in the rightward shift of the Ca2+ force
relation induced by cAMP-dependent phosphorylation (24).
The significance of these findings with respect to the dynamics of
contraction and relaxation were studied by Wolska et al. (32). Isolated myocytes from TG mice exhibited decreased
maximal rates of contraction and relaxation, though no change in the
absolute length of shortening. Detergent extracted fibers from TG mice exhibited significantly less maximum tension and ATPase activity than wild-type (WT) mice. The authors concluded that these changes in
dynamics were related either to the increased sensitivity of the
myofilament to Ca2+, or altered feedback effects of
force-bearing cross bridges on activation (7).
On the basis of these studies, we hypothesized that in perfused hearts
from mice overexpressing
-tropomyosin there would be an altered
force-Ca2+ relationship secondary to the increased
Ca2+ sensitivity of the myofilament. Also, myofilament
abnormalities would result in compensatory effects on Ca2+
handling. There is growing evidence that alterations in myofilament function lead to changes in Ca2+ handling (12,
14). Perez et al. (25) recently showed that in the
spontaneous hypertension and heart failure rat, Ca2+
cycling abnormalities were secondary to myofilament dysfunction. Also,
we (18) have shown that in a TG mouse expressing mutant troponin I-lacking protein kinase C phosphorylation sites there is
prolongation of Ca2+ transients and reduction of
intracellular Ca2+ levels with Ca2+-induced
inotropy. Because the sarcoplasmic reticulum is predominantly responsible for Ca2+ handling in the mouse heart
(3), we predicted that the altered Ca2+
handling would result in abnormal responses to altered heart rates.
Also, because Ca2+ cycling is an important determinant of
myocardial O2 consumption, we measured myocardial
O2 consumption during a series of positive and negative
inotropic interventions. To address this hypothesis, we studied
intracellular Ca2+ concentration
([Ca2+]i), myocardial O2
consumption, and force-frequency relationships in Langendorff perfused
mouse hearts.
 |
METHODS |
Study design.
All studies were performed on perfused mouse hearts, in age-matched
male FVB WT and TG mice (range 6-32 wk). The age matching was
consistent throughout all the experiments. In one group of experiments,
intracellular Ca2+ was measured with the
Ca2+-sensitive fluorescent probe rhod 2 along with
developed pressures. In a second group of experiments, inotropic
responses and myocardial O2 consumption were measured.
Experiments were performed at 8 Hz, which is close to the physiological
heart rate for the mouse. In a subset of the second group, measurements
were taken at 6, 8, and 10 Hz. All TG studies were performed in
line 10, which expresses an approximately twofold greater
amount of
-tropomyosin than
-tropomyosin protein
(23).
Perfused mouse hearts.
Anesthesia was induced with an intraperitoneal injection of
pentobarbital sodium (1.5-3.0 mg). The animal was then
anticoagulated with 100 units of heparin sodium. Hearts were
gravity perfused with a perfusion pressure of 60 mmHg and stimulated at
the physiological mouse heart rate of 8 Hz, unless otherwise stated.
The left ventricular diastolic pressure was set at 0-10 mmHg with
the use of a microsyringe. The modified Krebs solution used was
composed of 113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 0.5 mM
Na-EDTA, 28.0 mM NaHCO3, 5.5 mM glucose, 5.0 mM pyruvate,
2.5 mM CaCl2, and 50 µM octanoate, and was oxygenated
with 95% O2-5% CO2, with the pH adjusted to 7.4.
Measurement of intracellular
Ca2+.
The methods used to measure intracellular Ca2+ with rhod 2 in perfused hearts have been previously extensively described
(9-11, 19). Rhod 2 (100 µg for 2.5 mM experiments
and 200 µg for 1.5 mM experiments; Molecular Probes; Eugene, OR) was
dissolved with dimethyl sulfoxide (4 µl) and dH2O (200 µl), and loaded through the coronary perfusate. After the washout
period, serial measurements of fluorescence alternating with absorbance
were taken (10). Fluorescence recordings were taken at
high time resolution to allow quantification of changes in fluorescence
during the cardiac cycle. Excitation at 524 nm and emission at 589 nm
was used for fluorescence measurements. At 8 Hz, fluorescence data was
recorded for 10 s at 0.008 s intervals with an integration time
for each point of 0.0062 s, resulting in 16 points per beat. At 10 Hz, data were collected every 0.006 s with an integration time of 0.0042 s
resulting in 17 points per beat, and at 6 Hz data were collected every
0.01 s with an integration time of 0.0082 s resulting in 17 points
per beat.
Quantification of the relative amount of rhod 2 in the heart using
absorbance measurements was done by taking the ratio of absorbance at
524 nm (rhod 2 sensitive) to 589 nm (rhod 2 insensitive), which
eliminated the effect of motion as both wavelengths would be equally
affected by motion, though only 524 reflected the concentration of rhod
2 (9, 10). These wavelengths (524 and 589 nm) were chosen
because these were isosbestic points not affected by changes in
absorbance of myoglobin induced by O2 desaturation
(10). In solution, maximal rhod 2 absorbance is at 554 nm.
However, this wavelength is affected by changes in O2
saturation, the relative absorbance compared with 524 nm is decreased
due to inner filter effects, and it does not adequately correct for
changes in scattering (10). Dye absorbance
(Arhod2) was calculated according to the formula
|
(1)
|
where R524 is the reflectance intensity at the rhod
2-sensitive point of 524 nm, and R589 is the rhod
2-insensitive point, before ()0 and after
()rhod2 loading.
At the end of the perfusion protocol, maximal fluorescence, used in the
calculation of [Ca2+]i, was determined by
tetanizing the heart with a 20 mM bolus of Ca2+ chloride
without any energy substrate, and with 10 µM cyclopiazonic acid
(Sigma), which is a potent inhibitor of Ca2+-ATPase and
thus blocks Ca2+ uptake by the sarcoplasmic reticulum
(2). Fluorescence and pressure were monitored
continuously, and the point of maximal fluorescence was taken as the
point where pressure stabilized at a steady state. To account for
changes in light scattering properties from the heart during
tetanization, the maximal fluorescence was corrected by multiplying by
the ratio of R524 pretetanization to R524
during tetanization (10).
Intracellular Ca2+ was calculated using the formula
|
(2)
|
where Kd is the dissociation constant for
rhod 2 and Ca2+ [determined by in vitro calibration with
rhod 2 and myoglobin by del Nido et al. (9), and confirmed
by in vivo manganese quenching (11)] and is 710 nM,
Ft = fluorescence at time t,
Fmax = maximal fluorescence from tetanized heart, and
the fluorescence from the heart, assuming rhod 2 was not
Ca2+ bound, is given by F0 = Fb + a(Fmax
Fb), where Fb is the
background counts from the heart before dye loading, and a
is rhod 2 fluorescence in the absence of Ca2+/rhod 2 fluorescence in the presence of saturating Ca2+. For rhod
2, the value of a is ~0; thus for rhod 2, F0
was assumed to be equal to Fb.
To account for changes in dye concentration, Eq. 2 needs to
be modified to account for changes in absorbance (Arhod2,
Eq. 1) due to dye leakage
|
(3)
|
where At is dye absorbance at
time t, Amax is dye absorbance just
before tetanizing the heart. Amax is not
determined when heart has tetanized because of the marked influence of
the shape change and desaturation of myoglobin on the reflectance spectrum.
At perfusate Ca2+ 2.5 mM, intracellular Ca2+
was quantified at 8 Hz alone in n = 5 for both WT and
TG. Intracellular Ca2+ was also quantified at 6, 8, and 10 Hz (in alternating orders) in WT (n = 6) and TG
(n = 4) mice. In addition, force-frequency pressure
responses were also measured in a group of hearts without concomitant
intracellular Ca2+ measurements in WT (n = 10) and TG (n = 7) mice. Ca2+ and pressure
data from all of these groups are presented together where applicable
because results were consistent between groups. At perfusate
Ca2+ 1.5 mM, intracellular Ca2+ was quantified
at 8 Hz alone in WT (n = 3) and TG (n = 2).
Myocardial O2 consumption and
inotropic responses in perfused mouse hearts.
Because Ca2+ handling may be an important determinant of
myocardial O2 consumption, this was measured under a range
of inotropic states. Also, because a decrease in the expected rightward
shift of the force-Ca2+ relationship has been demonstrated
in these TG mice (24), we determined the significance of
this by giving the predominant
-adrenergic agonist dobutamine.
Myocardial O2 consumption was determined from influent and
effluent O2 content and coronary flow rate. A baseline
period, lasting ~30 min until repeated measurements of myocardial
O2 consumption and developed pressures were at steady state, was followed by an inotropic intervention. The following protocols were performed: 1) baseline perfusate
Ca2+ 2.5 mM, followed by the
-adrenergic agonist
dobutamine 0.9 µM (WT, n = 6; TG, n = 8), 2) baseline perfusate Ca2+ 2.5 mM, followed
by perfusate Ca2+ 3.5 mM (WT and TG, n = 6), and 3) baseline perfusate Ca2+ 1.5 mM,
followed by perfusate Ca2+ 0.5 mM (WT, n = 4; TG, n = 5). In addition, in n = 4 for both WT and TG, myocardial O2 consumption was measured
at 6, 8, and 10 Hz.
Data and statistical analysis.
Analysis of Ca2+ transients was performed after each
individual fluorescence data point had been converted to
[Ca2+] because the relationship between fluorescence and
[Ca2+]i may not be linear (7).
Ca2+ transient decay was then calculated from the peak of
the transient to 90% decay, and also the decay constant
Ca2+ was calculated using the exponential curve fitting,
Y = m1 · e
cx,
where Y is intracellular Ca2+,
m1 is the arbitrary constant, c is
the decay time constant, and x is time.
was
calculated from the first point after the peak of the Ca2+
transient to 90% of the transient decay. Because the asymptote is not
zero, the asymptote value was subtracted out from each data point
(6, 13).
Unpaired comparisons were performed using the unpaired
t-test. Repeated-measures analysis of variance (ANOVA) was
used for force-frequency data. Multiple comparisons were performed with ANOVA with Scheffé's test for subgroup analysis. Data are
expressed as means ± SE.
 |
RESULTS |
Pressures.
There was a marked negative force-frequency response in TG mice,
greater than that seen in WT mice (Fig.
1). No significant differences in
pressures or first derivative of pressure development over time
(dP/dt) were seen at 6 Hz, though there was significant elevation of diastolic pressures and reduction in peak-positive dP/dt at 8 and 10 Hz. Between 6 and 10 Hz, peak-positive
dP/dt decreased by 14 ± 2% in WT mice, though by
30 ± 3% in TG mice (P < 0.001). Developed
pressures (systolic-diastolic) were not significantly different at 6 or
8 Hz between WT and TG mice (6 Hz: 70 ± 1 vs. 70 ± 3 mmHg,
and 8 Hz: 59 ± 2 vs. 56 ± 2 mmHg, P = not
significant), though they were significantly reduced at 10 Hz in the TG
mice (42 ± 1 vs. 37 ± 2 mmHg, P < 0.05).
These effects at 10 Hz were not due to ischemia because
coronary flow did not change during the changes in heart rate. Coronary
flows in TG mice at 6, 8, and 10 Hz were 2.3 ± 0.1 ml, and in the
TG mice were 2.1 ± 0.1 ml/min.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Force-frequency relationships (6, 8, and 10 Hz, perfusate
Ca2+ 2.5 mM) in transgenic (TG) and wild-type (WT) mice.
Systolic pressure (A), diastolic pressure (B),
peak-positive first derivative of pressure development over time
(dP/dt) (C), and peak-negative dP/dt
(D). *P < 0.01; **P < 0.005, WT vs. TG mice.
|
|
Reduced intracellular
Ca2+ and altered
pressure-Ca2+
relationship.
At perfusate Ca2+ 2.5 mM, peak systolic intracellular
Ca2+, though not diastolic Ca2+, was reduced at
6, 8, and 10 Hz in TG mice compared with WT mice (Table
1). Because this was associated with
normal developed pressures at 6 and 8 Hz, at these frequencies, this
indicates an alteration in the pressure-Ca2+ relationship.
That Ca2+ levels are reduced and not normal and pressures
are normal and not increased indicates that there are compensatory
changes in Ca2+ handling to the altered myofilament
function (Fig. 2). This effect is less
marked at 10 Hz when both developed pressures and peak systolic
Ca2+ are reduced. There were no significant differences in
peak systolic, diastolic, or
Ca2+ by repeated-measures
ANOVA [P = not significant (NS)] between heart rates
within each group.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Examples of simultaneous recordings of left ventricular
pressure and intracellular Ca2+ (8 Hz, perfusate
Ca2+ 2.5 mM) in WT mice (A) and TG mice
(B) illustrating altered pressure-Ca2+
relationship. The pressure-Ca2+ relationship (C)
indicates a leftward shift in TG mice associated with the altered
pressure-Ca2+ relationship.
|
|
Additional fluorescence data from the perfusate Ca2+ 2.5 mM
experiments are presented in Table 2 and
indicate that the fundamental aspects of the fluorescence experiments
are similar between the two groups, such as background fluorescence,
maximal fluorescence after tetanization, and fluorescence increase
after rhod 2 loading. However, the ratio of
fluorescence to
diastolic fluorescence, which is a relative measure of intracellular
Ca2+ (10), is significantly reduced in TG
mice, and this agrees well with the ratio of
Ca2+ to
diastolic Ca2+, which is also significantly reduced in the
TG mice. These data show that the significant reduction in
intracellular Ca2+ in the TG mice is not an artifact of
abnormal rhod 2 loading, absorption measurements or the tetanization
procedure. At perfusate Ca2+ 1.5 mM, peak systolic and
systole-diastole intracellular Ca2+ were also reduced in
the TG mice (Fig. 3 and Table 1).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
Peak systolic intracellular Ca2+ and systolic
pressures at perfusate Ca2+ 1.5 and 2.5 mM. Decrease in
intracellular Ca2+ in the TG mice is proportionally similar
at both levels of perfusate Ca2+. *P < 0.05 and #P = 0.05, WT vs. TG.
|
|
Ca2+ transients.
In WT mice, Ca2+ transient intervals shortened as heart
rates increased (Fig. 4). When normalized
to the length of the cardiac cycle, the transient interval is seen to
increase with higher heart rates, indicating that there is less
available time for relaxation. In WT mice, shortening of the transient
occurred between both 6 and 8 Hz and 8 and 10 Hz, though the extent of
shortening was greater between 8 and 10 Hz (
Ca2+,
6-8 Hz:
4%; 8-10 Hz:
16%). In the TG mice, shortening
of the transient also occurred with increasing heart rates, though this was at 6-8 Hz and not between 8 and 10 Hz (
Ca2+,
6-8 Hz:
20%; 8-10 Hz: +5%). This altered pattern of
Ca2+ transient shortening with increased rate resulted in a
significant abbreviation of the Ca2+ transient at 8 Hz in
TG mice compared with WT mice, though not at 6 or 10 Hz. Examples of
perfusate Ca2+ 2.5 mM Ca2+ transients at 6, 8, and 10 Hz and normalized Ca2+ transients are shown in Fig.
5. There were no significant differences in Ca2+ transient duration at perfusate Ca2+
1.5 mM (8 Hz) between WT and TG mice (time to 90% decay: WT, 60 ± 4 vs. TG, 60 ± 10 ms, P = not significant).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of rate on intracellular Ca2+
transient decay (perfusate Ca2+ 2.5 mM). A: time
from peak of the transient to 90% decay. B: time from peak
of the transient to 90% normalized to heart rate (R-R interval).
C: Ca2+. D: Ca2+
normalized to R-R interval. *P < 0.05, TG vs. WT
mice.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
Examples of averaged Ca2+ transients (perfusate
Ca2+ 2.5 mM, 5-8 cycles) at 6 Hz (A), 8 Hz
(B), and 10 Hz (C), and averaged normalized
Ca2+ transients at 6 Hz (D), 8 Hz
(E), and 10 Hz (F). Peak systolic intracellular
Ca2+ is reduced in TG mice compared with WT mice, though
there is no difference in diastolic Ca2+. At 8 Hz, the
Ca2+ transient is abbreviated in TG mice, though at 6 and
10 Hz, there are no differences.
|
|
Increased myocardial O2 consumption and
altered pressure-myocardial O2 consumption
relationship.
There were no significant differences in developed pressures when
perfusate Ca2+ was varied from 0.5 to 3.5 mM, or with
dobutamine (Fig. 6A). There
were significant increases in myocardial O2 consumption at
all inotropic states studied in the TG mice compared with WT mice (all
P < 0.05, and P < 0.005; Fig.
6B). This difference was greater at perfusate
Ca2+ 0.5 mM (54%) compared with perfusate Ca2+
3.5 mM (15%), or with dobutamine (21%) (Fig. 6C). This
indicates an alteration in the pressure-myocardial O2
consumption relationship in the TG mice. Systolic and diastolic
pressures, balloon volumes, and effluent O2 saturations are
detailed in Table 3. These indicate that
the relationship of pressures to isovolumic volume is similar over a
wide range of inotropy, with only a few exceptions. For instance,
diastolic pressure was significantly elevated in TG mice only at
perfusate Ca2+ 2.5 mM (P < 0.05). Also, at
perfusate Ca2+ 2.5 mM only, though not other inotropic
states, coronary flow and effluent PO2 were
significantly lower in the TG mice (both P < 0.05).
Balloon volumes were significantly lower in the TG mice in the
perfusate Ca2+ range of 2.5-3.5 mM (P < 0.05), though there were no significant differences in the other
experiments. There were no differences in heart weight-to-body weight
ratios between WT and TG mice (WT = 0.0048 ± 0.0001, n = 16; TG = 0.0046 ± 0.0001, n = 19; P = NS).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 6.
A: developed pressure during
Ca2+-induced inotropy (0.5-3.5 mM) and dobutamine (0.9 µM) in WT and TG mice. B: myocardial O2
consumption during Ca2+-induced inotropy (0.5-3.5 mM)
and dobutamine (0.9 µM) in WT and TG mice. *P < 0.05 and **P < 0.005 WT vs. TG. Normal developed pressures
are seen at all inotropic levels in TG mice, though there is increased
myocardial O2 consumption throughout. C: % difference in myocardial O2 consumption between WT and TG
mice. Differences are greater at lower levels of perfusate
Ca2+. D: effects of rate (6-10 Hz) on
myocardial O2 consumption. There were no significant
differences within each group with altered heart rates.
*P < 0.05 WT vs. TG mice.
|
|
View this table:
[in this window]
[in a new window]
|
Table 3.
Systolic and diastolic pressures, balloon volume, coronary flow, and
effluent PO2 in WT and TG with altered
perfusate calcium and dobutamine
|
|
There was no significant difference in myocardial O2
consumption between 6, 8, and 10 Hz (repeated-measures ANOVA) within each group (Fig. 6D). As developed pressures were
significantly reduced at 10 Hz (though not at other heart rates), this
indicates a greater alteration in the pressure-myocardial
O2 consumption relationship at higher heart rates. Also,
because coronary flows did not change with heart rate (see above), and
myocardial O2 consumption remained elevated at all heart
rates, this indicates that the negative force-frequency relationship
and failure to abbreviate transients from 8 to 10 Hz in the TG mice are
not the result of ischemia.
 |
DISCUSSION |
The present study demonstrates that in TG mice
overexpressing
-tropomyosin there is an alteration in the
force-Ca2+ relationship with reduced peak systolic
intracellular Ca2+ levels though normal systolic pressures.
That intracellular Ca2+ is reduced and pressures are
normal, rather than normal Ca2+ and increased pressures,
indicates an adaptation in Ca2+ handling in response to the
altered myofilament function. There is an altered pattern of
Ca2+ transient abbreviation with increasing heart rates,
with greater shortening of the transient at lower heart rates in the TG
mice. There is increased myocardial O2 consumption over a
wide range of inotropy. All of these findings are modulated by
increasing heart rates, which are associated with marked left
ventricular dysfunction in TG mice. The altered force-Ca2+
relationship is less marked at 10 Hz because there are reduced developed pressures as well as reduced intracellular Ca2+.
Ca2+ transients are abbreviated at 8 Hz though not at 6 Hz
and 10 Hz. At 10 Hz, myocardial O2 consumption remains
elevated despite significant reductions in developed pressures,
indicating a greater alteration in the pressure-myocardial
O2 consumption relationship.
Functional abnormalities are not due to structural change in
-tropomyosin TG mice.
The TG mice overexpressing
-tropomyosin have been well
characterized. Several studies have demonstrated functional
abnormalities that appear to relate to altered myofilament function.
For instance, Muthuchamy et al. (23) have shown altered
diastolic function in perfused mouse hearts, though no abnormalities
were detected by light or electron microscopy, or with immunological
staining using a striated muscle-specific tropomyosin monoclonal
antibody. Subsequently, Wolska et al. (32) demonstrated
that there were reduced maximal rates of contraction and relaxation in
isolated myocytes, indicating that the isolated heart findings of
Muthuchamy et al. (23) and the present study are intrinsic
to the cells. Furthermore, there is no difference in heart
weight-to-body weight ratios in the present study, and throughout a
wide range of inotropy there are only minimal differences in systolic
or diastolic pressures and isovolumic balloon volumes. Furthermore, the
rate dependence of the abnormalities in the present study suggests that
these findings are not structural. Thus the findings in the present study are related to intracellular abnormalities.
Altered force-Ca2+
relationship and Ca2+
transients.
It is important to note that our measurements of intracellular
Ca2+ relate to cytosolic free Ca2+, and not the
total amount of Ca2+ cycled in a cardiac cycle, which also
includes Ca2+ bound to cytosolic proteins, such as troponin
C and other Ca2+-buffering proteins. There are several
potential explanations for the altered force-Ca2+
relationship and Ca2+ transients, including: 1)
sarcoplasmic reticulum function is altered, 2) troponin C
Ca2+ binding is increased because of the increased
Ca2+ sensitivity, and 3) there is increased
Ca2+ binding by cytosolic Ca2+ buffering
proteins other than troponin C.
Altered function of the sarcoplasmic reticulum may explain most, if not
all, of our findings. Indeed, in the mouse, the sarcoplasmic reticulum
is responsible for >90% of Ca2+ removal from troponin C
(3). The reduced peak systolic Ca2+ may relate
to reduced Ca2+ release from the sarcoplasmic reticulum,
presumably as a compensatory response to the increased myofilament
Ca2+ sensitivity. The abbreviated Ca2+
transients at 8 Hz may be secondary to the reduced levels of peak
systolic intracellular Ca2+ (4), because if
less Ca2+ is released, it may not take as long to take up
Ca2+ into the sarcoplasmic reticulum. However, this does
not explain the observation that the Ca2+ transient is not
abbreviated relative to WT with perfusate Ca2+ 2.5 mM at 6 and 10 Hz or perfusate Ca2+ 1.5 mM (8 Hz) when reduced peak
systolic intracellular Ca2+ is also seen. This suggests
therefore that the abbreviation of the Ca2+ transient is at
least in part related to a factor other than the reduced peak systolic
Ca2+, and that it is a compensatory response, of which one
explanation is enhanced uptake of intracellular Ca2+ by the
sarcoplasmic reticulum.
The frequency dependence of many of our findings may implicate the
sarcoplasmic reticulum. Frequency-dependent changes in force of
contraction are present in most mammalian species, and are also species
dependent. For instance, in the guinea pig, rabbit, and human
myocardium, there is an increase in force with increasing stimulation
frequency, though in the rat and mouse there is a negative force
frequency relationship (3). Sarcoplasmic reticulum Ca2+ ATPase and phospholamban are especially implicated in
the murine heart force frequency responses (16, 21).
Expression of sarcoplasmic reticulum Ca2+ ATPase and
phospholamban are unchanged in these mice (23), though
phosphorylation differences could account for the altered transients.
It is important to note that the supply of O2 to the myocardium in the TG mice is unchanged at the higher heart rates because coronary flow does not change, so this phenomenon is not a
consequence of ischemia. Also, because myocardial
O2 consumption does not change between 8 and 10 Hz, this
does not appear related to increased ATP utilization above that seen at
8 Hz.
The increased myocardial O2 consumption may provide
indirect evidence supporting this hypothesis of altered sarcoplasmic
reticulum function. During positive inotropy, there are two major
determinants of myocardial O2 consumption: ATP consumption
related to Ca2+ cycling and actomyosin ATPase activity
(20). Recently, Brandes et al. (5) estimated
that these factors each account for 50% of the energetic requirements
of myocardial contraction. It is known that in these TG mice the
economy of contraction related to actomyosin ATPase activity is
unchanged compared with WT mice (32), so that the
increased myocardial O2 consumption in the present study is
likely related to increased Ca2+ cycling. The increased
energy utilization may be a factor in the abbreviation in the
Ca2+ transient.
The reduced peak systolic Ca2+ may be a consequence of
increased troponin C Ca2+ binding. This factor alone,
however, does not explain how pressures are normal and not increased,
as would be expected with increased Ca2+ sensitivity of the
myofilament. One possibility is that the increased troponin C
Ca2+ binding is accompanied by the myofilament dysfunction,
as documented by Wolska et al. (32), which might result in
reduced systolic Ca2+ though normal pressures. However,
Allen and Kurihara (1) have stated that increased troponin
C Ca2+ binding will only have a relatively small effect on
the peak of the Ca2+ transient, because only 10-20%
of troponin C Ca2+ binding has occurred at the time of the
transient peak. The abbreviation of the Ca2+ transient may
also reflect increased troponin C Ca2+ binding. There have
been variable results in the literature regarding the effects of
increased Ca2+ sensitivity on intracellular
Ca2+ transients. Hajjar et al. (15) showed
prolonged transients in failing and nonfailing human myocardium with
the Ca2+ sensitizing agents EMD-57033 and ORG-30029.
However, Lee and Allen (17) have shown that with the
Ca2+ sensitizing agent EMD-53998 there is abbreviation of
the Ca2+ transient. Lee and Allen (17)
addressed the issues that might give rise to a shortened or prolonged
transient in a computer model based on the Ca2+ fluxes in
and out of the cell, Ca2+ binding to troponin C, and the
attachment of cross bridges. This model also predicted shortening of
the Ca2+ transient when the troponin C binding constant for
Ca2+ was increased by a factor of 2. However, if the
feedback between tension and the troponin Ca2+ binding
constant were removed, the time course of the transient decay was
prolonged. The shortened Ca2+ transient was attributed to
smaller Ca2+ efflux from troponin C, so that cytosolic
Ca2+ falls more rapidly. However, this hypothesis does not
explain the changes in the relative durations of the transient at
different heart rates seen in the present study in the
-tropomyosin
TG mice.
Increased cytosolic Ca2+ binding by proteins other than
troponin C may also produce similar findings, as in the present study. Indeed, it is interesting to note that in diseased myocytes, gene transfer of the Ca2+ buffer parvalbumin (that is not
normally found in cardiac myocytes) corrects diastolic dysfunction with
abbreviation of Ca2+ transients (31). With
increased cytosolic Ca2+ binding, a blunted response to
altered levels of intracellular Ca2+ would be expected.
However, the experiments in the present study, with a wide range of
perfusate Ca2+ and dobutamine demonstrating normal
pressures relative to WT at all levels of inotropy, may not
support this hypothesis.
Potential limitations.
We used rhod 2 to study intracellular Ca2+, which some
investigators (30) have found in mitochondria. Our
previous experiments (9, 19) have shown that there is
predominant cytosolic loading and it is possible that this discrepancy
is the consequence of very different loading conditions in different
models used by other investigators (30). Nevertheless, we
cannot exclude some contribution of mitochondrial rhod-2 fluorescence
to our measurements of intracellular Ca2+. Our methods do
have the advantage that the same isolated perfused heart technique is
used to measure pressures, myocardial O2 consumption, and
intracellular Ca2+, so these measurements are all directly
comparable. We currently obtain a limited number of time points for
each transient (n = 16 or 17), which limits our ability to
detect differences in Ca2+ transient duration, especially
at 50% of the decay time when the decay is very rapid. Also, we have
not studied intracellular Ca2+ over a wide range of
perfusate Ca2+, due to instability of the TG hearts at the
high-perfusate Ca2+ for the relatively long time required
to perform these experiments.
In conclusion, perfused mouse hearts from TG mice overexpressing
-tropomyosin demonstrate altered pressure-Ca2+ and
pressure-myocardial O2 consumption relationships, and
altered pressure responses and Ca2+ transient abbreviation
with increased heart rates. The reduced intracellular Ca2+
and increased myocardial O2 consumption appear at least in
part compensatory mechanisms to the altered myofilament function.
Overexpression of
-tropomyosin to levels greater than seen in those
mice used in the present study is associated with marked cardiac
enlargement and dysfunction (22). This hypertrophy can be
prevented by inhibition of the Ca2+/calmodulin-dependent
protein phosphatase calcineurin (29), implying a direct
link with Ca2+ homeostasis. It is interesting to speculate
that the abnormalities in Ca2+ homeostasis and myocardial
O2 consumption demonstrated herein may directly contribute
to hypertrophy when
-tropomyosin is expressed at greater levels, as
has been proposed for other TG models involving Ca2+
signaling (8).
 |
ACKNOWLEDGEMENTS |
This study was supported by National Heart, Lung, and
Blood Institute Grants HL-03826 (to G. A. MacGowan) and HL-40354
(to A. P. Koretsky), National Institutes of Health Grant RR-03631 (to the Pittsburgh Nuclear Magnetic Resonance Center for Biomedical Research), and by the National Institute of Neurological Disorders and
Stroke intramural research program.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: G. A. MacGowan, Cardiovascular Institute of the University of Pittsburgh Medical Center, S550 Scaife Hall, 200 Lothrop St., Pittsburgh, PA 15213 (E-mail: macgowanga{at}msx.upmc.edu).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 13 December 2000; accepted in final form 27 August 2001.
 |
REFERENCES |
1.
Allen, DG,
and
Kurihara S.
The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle.
J Physiol (Lond)
327:
79-94,
1982[Abstract/Free Full Text].
2.
Backx, PH,
Gao WD,
Azan-Backx M,
and
Marban E.
The relationship between contractile force and intracellular [Ca2+] in intact rat cardiac trabeculae.
J Gen Physiol
105:
1-19,
1998[Abstract/Free Full Text].
3.
Bers, DM.
Calcium fluxes involved in the control of cardiac myocyte contraction.
Circ Res
87:
275-281,
2000[Free Full Text].
4.
Bers, DM,
and
Berlin JR.
Kinetics of [Ca]i decline in cardiac myocytes depend on peak [Ca]i.
Am J Physiol Cell Physiol
265:
C271-C277,
1993.
5.
Brandes, R,
and
Bers DM.
Analysis of mechanisms of mitochondrial NADH regulation in cardiac trabeculae.
Biophys J
77:
1666-1682,
1999[Web of Science][Medline].
6.
Camacho, SA,
Brandes R,
Figuerdo VM,
and
Weiner MW.
Ca2+ transients decline and myocardial relaxation are slowed during low flow ischemia in rat hearts.
J Clin Invest
93:
951-957,
1994.
7.
Campbell, K.
Rate constant of muscle force redevelopment reflects cooperative activation as well as cross-bridge kinetics.
Biophys J
72:
254-262,
1997[Web of Science][Medline].
8.
Chien, KR.
Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.
J Clin Invest
105:
1339-1342,
2000[Web of Science][Medline].
9.
Del Nido, PJ,
Glynn P,
Buenaventura P,
and
Koretsky AP.
Fluorescence measurement of calcium transients in perfused rabbit heart using rhod 2.
Am J Physiol Heart Circ Physiol
274:
H728-H741,
1998[Abstract/Free Full Text].
10.
Du, C,
MacGowan GA,
Farkas DL,
and
Koretsky AP.
Calcium measurements in perfused mouse heart: quantitating fluorescence and absorbance of rhod-2 by application of photon migration theory.
Biophys J
80:
549-561,
2001[Web of Science][Medline].
11.
Du, C,
MacGowan GA,
Farkas DL,
and
Koretsky AP.
Calibration of calcium dissociation constant of rhod-2 in vivo in perfused mouse heart using manganese quenching.
Cell Calcium
29:
217-227,
2001[Web of Science][Medline].
12.
Frey, N,
McKinsey TA,
and
Olson EN.
Decoding calcium signals involved in cardiac growth and function.
Nat Med
11:
1221-1227,
2000.
13.
Fry, C.
A numerical method for the calculation of the time constant of exponential functions.
Cardiovasc Res
27:
1552-1553,
1993[Web of Science][Medline].
14.
Gao, WD,
Perez NG,
Seidman CE,
Seidman JG,
and
Marban E.
Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy.
J Clin Invest
103:
661-666,
1999[Web of Science][Medline].
15.
Hajjar, RJ,
Schmidt U,
Helm P,
and
Gwathmey JK.
Ca++ sensitizers impair cardiac relaxation in failing human myocardium.
J Pharmacol Exp Ther
280:
247-254,
1997[Abstract/Free Full Text].
16.
Kadambi, VJ,
Ball N,
Kranias EG,
Walsh RA,
and
Hoit BD.
Modulation of force-frequency relation by phospholamban in genetically engineered mice.
Am J Physiol Heart Circ Physiol
276:
H2245-H2250,
1999[Abstract/Free Full Text].
17.
Lee, JA,
and
Allen DG.
EMD 53998 sensitizes the contractile proteins to calcium in intact ferret ventricular muscle.
Circ Res
69:
927-936,
1991[Abstract/Free Full Text].
18.
MacGowan, GA,
Du CW,
Cowan DB,
Stamm C,
McGowan FX,
Solaro RJ,
Koretsky AP,
and
del Nido PJ.
Ischemic dysfunction in transgenic mice expressing mutant troponin I lacking protein kinase C phosphorylation sites.
Am J Physiol Heart Circ Physiol
280:
H835-H843,
2001[Abstract/Free Full Text].
19.
MacGowan, GA,
Du C,
Glonty V,
Suhan JP,
Koretsky AP,
and
Farkas DL.
Rhod-2 based measurements of intracellular calcium in the perfused mouse heart: cellular and subcellular localization, and response to positive inotropy.
J Biomed Opt
6:
23-30,
2001[Web of Science][Medline].
20.
MacGowan, GA,
and
Koretsky AP.
Inotropic and energetic effects of altering the force-calcium relationship: mechanisms, experimental results and potential molecular targets.
J Card Fail
6:
144-156,
2000[Web of Science][Medline].
21.
Meyer, M,
Bluhm WF,
He H,
Post SR,
Giordano FJ,
Lew WYW,
and
Dillman WH.
Phospholamban-to-SERCA ratio controls the force-frequency relationship.
Am J Physiol Heart Circ Physiol
276:
H779-H785,
1999[Abstract/Free Full Text].
22.
Muthuchamy, M,
Boivin GP,
Grupp IL,
and
Wieczorek DF.
-tropomyosin induces severe cardiac abnormalities.
J Mol Cell Cardiol
30:
1545-1557,
1998[Web of Science][Medline].
23.
Muthuchamy, M,
Grupp IL,
Grupp G,
O'Toole BA,
Kier AB,
Boivin GP,
Neumann J,
and
Wieczorek DF.
Molecular and physiological effects of overexpressing striated muscle
-tropomyosin in the adult murine heart.
J Biol Chem
270:
30593-30603,
1995[Abstract/Free Full Text].
24.
Palmiter, KA,
Kitada Y,
Muthuchamy M,
Wieczorek DF,
and
Solaro RJ.
Exchange of
- for
-tropomyosin in hearts of transgenic mice induces changes in thin filament response to Ca2+ strong cross bridge binding, and protein phosphorylation.
J Biol Chem
271:
11611-11614,
1996[Abstract/Free Full Text].
25.
Perez, NG,
Hashimoto K,
McCune S,
Altschuld RA,
and
Marban E.
Origin of contractile dysfunction in heart failure. Calcium cycling versus myofilaments.
Circulation
99:
1077-1083,
1999[Abstract/Free Full Text].
26.
Pieples, K,
and
Wieczorek DF.
Tropomyosin 3 increases striated muscle isoform diversity.
Biochemistry
39:
8291-8297,
2000[Medline].
27.
Schachat, FH,
Diamond MS,
and
Brandt PW.
Effect of different troponin T-tropomyosin combinations on thin filament activation.
J Mol Biol
1987:
551-4,
1987.
28.
Solaro, RJ,
and
Rarick HM.
Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments.
Circ Res
83:
471-480,
1998[Abstract/Free Full Text].
29.
Sussman, MA,
Lim HW,
Gude N,
Tagen T,
Olson EN,
Robbins J,
Colbert MC,
Gualberto A,
Wieczorek DF,
and
Molkentin JD.
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Science
281:
1690-1693,
1998[Abstract/Free Full Text].
30.
Trollinger, DR,
Cascio WE,
and
Lemasters JJ.
Selective loading of rhod-2 into mitochondria shows Ca2+ transients during the contractile cycle in adult rabbit cardiac myocytes.
Biochem Biophys Res Commun
236:
738-742,
1997[Web of Science][Medline].
31.
Wahr, PA,
Michele DE,
and
Metzger JM.
Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes.
Proc Natl Acad Sci USA
96:
11982-11985,
1999[Abstract/Free Full Text].
32.
Wolska, BM,
Keller RS,
Evans CC,
Palmiter KA,
Phillips RM,
Muthuchamy M,
Oehlenschlager J,
Wieczorek DF,
de Tombe PP,
and
Solaro RJ.
Correlation between myofilament response to Ca2+ and altered dynamics of contraction and relaxation in transgenic cardiac cells that express
-tropomyosin.
Circ Res
84:
745-751,
1999[Abstract/Free Full Text].
Am J Physiol Heart Circ Physiol 281(6):H2539-H2548